(PharmaNewsWire.Com, July 14, 2021 ) According to research report the competent cells market is projected to reach USD 2.22 billion by 2022 from USD 1.37 billion in 2017, at a CAGR of 10.2%.
The advancements in molecular cloning research due to the emergence of new technologies and the growing commercial demand for molecular cloned products and recombinant proteins are major factors that are driving the growth of this market.
By type, the chemically competent cells segment is expected to dominate the market in 2017
Based on the type of competent cells, the market is segmented into chemically competent cells and electrocompetent cells. The growth of the chemically competent cells segment can be attributed to the rising intensity of research (due to technological advancement) and availability of government support, along with the growing market demand for molecular cloned products.
By application, the cloning segment is expected to dominate the market in 2017
Based on application, the competent cells market is broadly segmented into cloning, protein expression, and other applications. Cloning is expected to command the largest share of this market in 2017. Increasing research on cloning, driven by government support and funding is among the major factors driving market growth in this segment. The cloning application is further segmented into subcloning & routine cloning, phage display library construction, toxic/unstable DNA cloning, and high-throughput cloning. Similarly, other applications of competent cells include mutagenesis, single-stranded DNA production, lentiviral vector production, and large plasmid transformation.
North America to dominate the competent cells market in 2017
By region, the global competent cells market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World (RoW). In 2017, North America is expected to account for the largest share of the market. This can be attributed to the increasing intensity of research due to technological advancement and increasing commercial needs for genomic and protein expressed products, in North American countries.
Key players operating in the competent cells market include Merck KGaA (Germany), Promega Corporation (U.S.), Thermo Fisher Scientific, Inc. (U.S), New England Biolabs (U.S.), Takara Bio (Japan), Agilent Technologies (U.S.), Lucigen (Epicenter) (Illumina) (U.S.), QIAGEN N.V. (Germany), OriGene Technologies (U.S.), Bioline (U.K.), Zymo Research (U.S.), Beijing TransGen Biotech Co., Ltd. (China), Source BioScience (U.K.), IBA GmBH (Germany), Genewiz (U.S.), BioDynamics Laboratory, Inc. (Japan), GCC Biotech (India), SMOBIO Technology (Taiwan), GeneScript Corporation (U.S.), Bio-Rad Laboratories (U.S.), Life Technologies (India) Pvt. Ltd., Cell Applications, Inc. (U.S.), Delphi Genetics (Belgium), Scarab Genomics, LLC (U.S.), and Yeastern Biotech Co., Ltd. (Taiwan).
Target Audience for this Report:
> Competent cell manufacturers > Research instrument manufacturers > Competent cell distributors > Various research and consulting companies > Research laboratories and research institutes > Universities and CROs
This report aims to provide insights into the global competent cells market. It provides valuable information on competent cells type, application, and end user. Details on regional markets for these segments are also presented in this report. In addition, leading players in the market are profiled to understand the strategies undertaken by them to be competitive in this market.
Contact: Mr. Aashish Mehra MarketsandMarkets™ INC. 630 Dundee Road Suite 430 Northbrook, IL 60062 USA: +1-888-600-6441 sales@marketsandmarkets.com
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
